BioXcel Therapeutics reaches 50% enrollment in SERENITY At-Home Phase 3 trial for BXCL501

BioXcel Therapeutics, Inc.

100 patients enrolled out of 200 expected (50% of total); 24 sites open as of March 20, 2025.
Trial evaluates BXCL501 (sublingual dexmedetomidine film) for acute agitation in bipolar disorder or schizophrenia at home.
Topline data expected in second half of 2025 to support sNDA for expanded IGALMI label.
Enrollment began September 2024; no safety or efficacy results reported yet.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.